Exhibits 4 iron, 4 sulfur cluster binding activity; iron-responsive element binding activity; and regulatory region RNA binding activity. Involved in several processes, including cellular response to decreased oxygen levels; cellular response to epidermal growth factor stimulus; and response to iron ion. Localizes to axon; cytosol; and neuronal cell body. Used to study anemia. Biomarker of anemia; hyperinsulinism; and iron deficiency anemia. Human ortholog(s) of this gene implicated in Alzheimer's disease. Orthologous to human IREB2 (iron responsive element binding protein 2); PARTICIPATES IN doxorubicin response pathway; iron homeostasis pathway; INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dinitrotoluene.
[TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of IREB2 mRNA, Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to IREB2 gene]
[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein, Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein]
[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein, Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein]
Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein], Deferoxamine results in increased expression of and results in increased activity of IREB2 protein
[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein, Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein]
[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein, Deferoxamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of IREB2 protein]
[IREB2 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA, Oxidopamine promotes the reaction [IREB2 protein results in decreased expression of SLC40A1 mRNA]
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IREB2 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IREB2 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of IREB2 protein] more ...
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
